Effects of intraoperative administration of atrial natriuretic peptide

Atrial Natriuretic Peptide for Management of Acute Kidney Injury

“…group) (21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39). Eleven studies involving 818 participants satisfied our review criteria for the prevention of AKI category (21,(23)(24)(25)27,28,30,(35)(36)(37)(38). Eight studies involving 1043 participants were included under the treatment of AKI category (22,26,29,(31)(32)(33)(34)39).…”

“…Six studies used urodilatin preparations (23,26,29,30,32,33), and other studies used human ANP preparation. Most of the prevention studies were conducted with low-dose ANP preparations (21,24,25,27,30,(35)(36)(37)(38). One prevention study designed to assess the effectiveness of ANP in radiocontrast nephropathy was a dose-response trial that involved administration of both low and high doses of ANP (28).…”

“…In the prevention cohort, five studies were of low quality (24,25,30,37,38), five were of moderate quality (21,27,28,35,36), and one was of high quality (23). Among the treatment studies, one was of low quality (34), four were of moderate quality (26,29,32,33), and three were of high quality (22,31,39).…”

Nesiritide and clinically relevant outcomes in cardiac surgery: a meta-analysis of randomized studies

“…Excluding 3 non pertinent titles or abstracts, we retrieved six studies in complete form and assessed them according to the selection criteria, (22)(23)(24)(25)(26)(27) which were included in the final analysis after the correspondent authors confirmed that there was no overlapping and/or duplicate publication. Five of these 6 studies were identified through database searches, while snowballing identified the sixth study.…”

Is Human Atrial Natriuretic Peptide (hANP) Effective as an Additive to Cardioplegic Solution During Cardiac Surgery?

“…vascular resistance in the early postoperative phase, 6 as well as favorable clinical findings such as a reduced incidence of postoperative arrhythmia and heart failure, not only in the early postoperative phase, but also in the long-term. 8 Kitakaze et al reported the findings of a prospective multi-center study, which demonstrated that low-dose intravenous infusion of hANP (0.025 μg · kg -1 · min -1 ) reduced infarct size, as evaluated by total CK levels, and increased left ventricular ejection fraction at 6-12 months after acute myocardial infarction.…”